Your search
Results 1,028 resources
-
Background:Lipedema, a chronic condition affecting 11% of women, causes abnormal fat buildup in the lower limbs, leading to disproportionate body...
-
BACKGROUNDLipedema is a chronic disorder characterized by disproportionate accumulation of subcutaneous fat, most commonly affecting the extremities,...
-
Background: Lipedema is a common, female-predominant disorder characterized by disproportionate, painful lower-limb adipose tissue, and it still lacks an objective biomarker, a disease-modifying therapy, or consensus on whether its core lesion is inflammatory. Its molecular literature is openly contradictory, reporting both immune enrichment and immune down-regulation in the same gluteofemoral depot. Because the dominant morbidity is pain rather than adipose mass, this ambiguity carries direct clinical cost. We therefore asked the following three questions: whether the reported molecular hallmarks survive control for cell-type composition, whether pain and adipose volume behave as separable endpoints, and what the germline architecture implies about the primary lesion. Materials and methods: From a theory-neutral standpoint, we reprocessed the largest publicly deposited adipose bulk RNA-seq dataset of lipedema (14 women with lipedema versus seven controls, paired by depot) with Salmon (College Park, MD: University of Maryland) and DESeq2 (Seattle, WA: Bioconductor Project), estimated cell-type composition by single-sample gene-set enrichment (ssGSEA), and refitted differential expression with leukocyte and erythroid composition covariates to test identifiability. We also synthesized published treatment cohorts (pain versus volume) and reviewed the architecture of germline genome-wide association studies (GWAS). Results: There is no transcriptional lipolytic brake (ADRA2A +0.001; lipases unchanged or mildly up). The apparent immune down-regulation is not identifiable from blood content; adjusting for tissue composition reduces genome-wide-significant genes from 1,501 to four, with blood content correlated with disease at r approximately -0.7, so bulk data can neither establish nor exclude immune involvement, including the NLRP3 inflammasome. Pain and adipose volume are dissociable across treatments, so body weight is a confounded endpoint. The germline architecture reported to date (GRB14-COBLL1, VEGFA, RSPO3, ADAMTS9) is adipo-vascular and extracellular-matrix-based rather than immune, although the largest contributing study defined cases by a bioimpedance proxy rather than by clinical diagnosis. Conclusions: Lipedema's inflammatory status is currently undecidable from composition-confounded bulk tissue rather than settled, which explains the field's contradictory literature; the germline evidence, limited by its case definitions, supports as a hypothesis an adipo-vascular and connective program rather than a primary immune lesion; and pain, not weight, should anchor trials. We specify, but do not perform, the single decisive experiment - paired thigh-versus-abdomen single-nucleus RNA-seq with explicit composition control.
-
Are you newly diagnosed with lipedema, a painful adipose tissue disorder? Maybe you have had the condition for years and are looking for ideas for self-care from a holistic perspective.In this book you will learn:Treatment goals for lipedema / lipoedemaTips for reducing pain and inflammationHow to boost your lymphatic systemIf you are looking for a research-packed guide to caring for lipedema, read this book!Praise for Lipedema Treatment Guide:Steven Dean, DO, FACP, RPVI, Professor of Clinical Internal Medicine, Ohio State University Wexner Medical Center calls the Lipedema Treatment Guide "incredibly well-written and informative" and has added it to his patient lipedema handout.Jacqui Beutel teaches Decongestive Lymphatic Therapy courses in Australia and New Zealand and gives copies of the Lipedema Treatment Guide to her students.
-
An evidence-based guide to current understanding of lipedema, its causes and possible treatments, addressing what is known through human studies, what is unknown and needs investigating, and what is likely to emerge. Lipedema (or lipoedema) is a chronic lymphatic disorder in which abnormal levels of fat build up disproportionately in certain areas of the body, most commonly the hips, bottom and legs. Almost exclusively affecting women, who may seek help for years only to be met with ongoing anti-fat stereotyping, its significant life-changing impact has only recently been recognized, clinically and in terms of research funding. Even though research is now accelerating, there is still much left to be discovered. This book brings together the current knowns, unknowns and conjectures as a comprehensive resource for researchers, clinicians and patients seeking a roadmap to potentially improving the lives of up to 17 million women in the US and 350 million worldwide.
-
Lipedema is a chronic and progressive disorder, a primary lipotrophy characterized by abnormal fat deposition, primarily in the buttocks and legs bilaterally. It is symmetrical and disproportionate. It is estimated to affect 10 to 18% of women in Europe and approximately 12.3% of the Brazilian female population.
Explore
Topic
- Lipedema
- Genetics (19)
- Guidelines and Consensus (42)
- LF Funded (53)
- Open Access (362)
- Original studies and data (403)
- Patient journey (33)
- Personal management (diet, excercise, nutrition) (44)
- Review (346)
- Therapeutics (76)
Resource type
- Blog Post (4)
- Book (26)
- Book Section (33)
- Conference Paper (15)
- Document (5)
- Journal Article (893)
- Magazine Article (4)
- Newspaper Article (1)
- Patent (1)
- Preprint (8)
- Presentation (2)
- Report (17)
- Thesis (7)
- Web Page (12)
Publication year
-
Between 1900 and 1999
(69)
- Between 1910 and 1919 (2)
-
Between 1940 and 1949
(2)
- 1940 (2)
- Between 1950 and 1959 (3)
- Between 1960 and 1969 (6)
- Between 1970 and 1979 (6)
- Between 1980 and 1989 (26)
- Between 1990 and 1999 (24)
-
Between 2000 and 2026
(948)
- Between 2000 and 2009 (102)
- Between 2010 and 2019 (240)
- Between 2020 and 2026 (606)
- Unknown (11)
Publication
- Open Access (362)